TABLE 2.
Characteristics of diseases that developed in primary recipientsa
| Mouse group (n) | Time of death or sacrifice (days post-Tx)b | No. with
|
No. of NC (106)/femur (% BM blast)b | Spleen wt (g)b | Clonality | Disease | |
|---|---|---|---|---|---|---|---|
| HL paralyses | PBL blastosis | ||||||
| neo control (4) | 56c | 0 | 0 | 19.0 ± 4 (<1) | 0.1 ± 0.01 | Oligo/poly | NOD |
| Hoxa9 nonleukemic (3) | 56c | 0 | 0 | 19.0 ± 5 (<1) | 0.13 ± 0.01 | Oligo/poly | NOD |
| Hoxa9 leukemic (4) | 167 ± 32d | 0 | 4 | 22.5 ± 5 (70 ± 20) | 0.6 ± 0.1 | Mono/bi | AML |
| E2A-Pbx1a (6) | 51 ± 3e | 6 | 0 | 7.0 ± 2 (25 ± 8) | 0.7 ± 0.3 | Poly | MPS |
| Hoxa9 + E2A-Pbx1a (6) | 39 ± 2 | 0 | 6 | 17.0 ± 8 (90 ± 5) | 0.8 ± 0.3 | Oligo | AML |
a
Abbreviations: Tx, transplantation; HL, hind leg; PBL, peripheral blood; NC, nucleated cells; NOD, no observed disease; AML, acute myeloid leukemia; MPS, myeloproliferative disorder.
b
Results are expressed as mean values ± SD.
c
The neo control and Hoxa9 nonleukemic mice were healthy at the time of sacrifice. Additional data for the three nonleukemic Hoxa9 mice (mice 1 to 3) sacrificed 56 days after transplantation are presented in Fig. 3, 6A and B, and 7B.
d
Sacrificed when presenting with acute leukemia (mice 4 to 7 in Fig. 4A and B and 7B).
e
Sacrificed when presenting with hind leg paralyses.